口腔鳞状细胞癌（OSCC）是一种常见的恶性肿瘤，具有高致死率，对人体的身体和心理健康构成了巨大威胁。随着科学研究的进展，多种癌症治疗方法被用于OSCC的治疗。然而，OSCC的预后并没有显著改善。二甲双胍已被公认为糖尿病治疗的一线药物，并且最新研究表明二甲双胍对肿瘤进展具有显著的抑制作用。二甲双胍不仅可以影响肿瘤细胞的能量代谢，还可以通过调节肿瘤微环境和肿瘤干细胞发挥抗肿瘤作用。本综述总结了二甲双胍在OSCC中的分子机制及其抗癌机制。此外，本文还总结了二甲双胍的副作用及其在OSCC治疗中的未来前景。© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Oral squamous cell carcinoma (OSCC) is one of the most common malignancies with high mortality, posing a great threat to both human physical and mental health. With the advancement of scientific research, a variety of cancer therapies have been used for OSCC treatment. However, the prognosis of OSCC shows no significant improvement. Metformin has been recognized as the first-line drug for the treatment of diabetes, and recent studies have shown that metformin has a remarkable suppressive effect on tumor progression. Metformin can not only affect the energy metabolism of tumor cells but also play an anti-tumor role by modulating the tumor microenvironment and cancer stem cells. In this review, the molecular mechanism of metformin and its anti-cancer mechanism in OSCC are summarized. In addition, this article also summarizes the side effects of metformin and the future prospects of its application in the treatment of OSCC.© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.